

Gerardo Nigro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8031825/publications.pdf>

Version: 2024-02-01

98
papers

1,530
citations

304368

22
h-index

433756

31
g-index

98
all docs

98
docs citations

98
times ranked

1563
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole. <i>European Heart Journal</i> , 2021, 42, 508-516.	1.0	69
2	Clinical characteristics and prognosis of hospitalized COVID-19 patients with incident sustained tachyarrhythmias: A multicenter observational study. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13387.	1.7	54
3	Effects of closed-loop stimulation vs. DDD pacing on haemodynamic variations and occurrence of syncope induced by head-up tilt test in older patients with refractory cardioinhibitory vasovagal syncope: the Tilt test-Induced REsponse in Closed-loop Stimulation multicentre, prospective, single blind, randomized study. <i>Europace</i> , 2018, 20, 859-866.	0.7	48
4	Atrial Fibrillation in COVID-19: From Epidemiological Association to Pharmacological Implications. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 138-145.	0.8	41
5	Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. <i>Therapeutic Advances in Drug Safety</i> , 2017, 8, 67-75.	1.0	40
6	Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves. <i>Clinical Therapeutics</i> , 2019, 41, 2549-2557.	1.1	40
7	Use of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Malignancy: Clinical Practice Experience in a Single Institution and Literature Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 370-376.	1.5	39
8	Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 364-369.	1.5	38
9	COVID-19 and Heart: From Clinical Features to Pharmacological Implications. <i>Journal of Clinical Medicine</i> , 2020, 9, 1944.	1.0	36
10	Electrocardiographic Presentation, Cardiac Arrhythmias, and Their Management in β -Thalassemia Major Patients. <i>Annals of Noninvasive Electrocardiology</i> , 2016, 21, 335-342.	0.5	34
11	Direct Oral Anticoagulants in Octogenarians With Atrial Fibrillation: It Is Never Too Late. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 73, 207-214.	0.8	33
12	The Role of the Atrial Electromechanical Delay in Predicting Atrial Fibrillation in Myotonic Dystrophy Type 1 Patients. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 65-72.	0.8	32
13	Early electrocardiographic evaluation of atrial fibrillation risk in beta-thalassemia major patients. <i>International Journal of Hematology</i> , 2011, 93, 446-451.	0.7	31
14	Atrial Fibrillation and Malignancy: The Clinical Performance of Non-Vitamin K Oral Anticoagulants—A Systematic Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 205-214.	1.5	30
15	Increased Heterogeneity of Ventricular Repolarization in Obese Nonhypertensive Children. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2010, 33, 1533-1539.	0.5	29
16	ACE inhibition to slow progression of myocardial fibrosis in muscular dystrophies. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 330-337.	2.3	29
17	Early onset of cardiomyopathy and primary prevention of sudden death in X-linked Emery-Dreifuss muscular dystrophy. <i>Neuromuscular Disorders</i> , 2010, 20, 174-177.	0.3	27
18	Heterogeneity of Ventricular Repolarization in Newborns With Severe Aortic Coarctation. <i>Pediatric Cardiology</i> , 2012, 33, 302-306.	0.6	26

#	ARTICLE	IF	CITATIONS
19	Cardiac resynchronization therapy and electrical storm: results of the OBSERVO registry on long-term outcome of ICD patients (OBSERVO-ICD). <i>Europace</i> , 2018, 20, 979-985.	0.7	26
20	Real-life Performance of Edoxaban in Elderly Patients With Atrial Fibrillation: a Multicenter Propensity Score-Matched Cohort Study. <i>Clinical Therapeutics</i> , 2019, 41, 1598-1604.	1.1	26
21	The Effect of Sacubitril/Valsartan on Device Detected Arrhythmias and Electrical Parameters among Dilated Cardiomyopathy Patients with Reduced Ejection Fraction and Implantable Cardioverter Defibrillator. <i>Journal of Clinical Medicine</i> , 2020, 9, 1111.	1.0	26
22	Physical Activity Measured by Implanted Devices Predicts Atrial Arrhythmias and Patient Outcome: Results of IMPLANTED (Italian Multicentre Observational Registry on Patients With Implantable) Tj ETQq0 0 0 rgBT 10 rlock 24 Tf 50 6	1.0	24
23	Impact on All-Cause and Cardiovascular Mortality of Cardiac Implantable Electronic Device Complications. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 382-392.	1.3	24
24	Right Atrial Appendage Versus Bachmann's Bundle Stimulation: A Two-Year Comparative Study of Electrical Parameters in Myotonic Dystrophy Type 1 Patients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 1191-1196.	0.5	22
25	Impact of Continuous Positive Airway Pressure Therapy on Atrial Electromechanical Delay in Obesity-Hypoventilation Syndrome Patients. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 327-334.	0.8	22
26	Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 206-212.	1.0	22
27	Optimal Site for Atrial Lead Implantation in Myotonic Dystrophy Patients: The Role of Bachmann's Bundle Stimulation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2008, 31, 1463-1466.	0.5	21
28	Atrial Septal Aneurysms and Supraventricular Arrhythmias: The Role of Atrial Electromechanical Delay. <i>Echocardiography</i> , 2015, 32, 1504-1514.	0.3	21
29	ICD role in preventing sudden cardiac death in Emery-Dreifuss muscular dystrophy with preserved myocardial function: 2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy. <i>Europace</i> , 2015, 17, 337-337.	0.7	21
30	Right atrial preference pacing algorithm in the prevention of paroxysmal atrial fibrillation in myotonic dystrophy type 1 patients: a long term follow-up study. <i>Acta Myologica</i> , 2012, 31, 139-43.	1.5	21
31	The heart and cardiac pacing in Steinert disease. <i>Acta Myologica</i> , 2012, 31, 110-6.	1.5	21
32	The Main Determinant of Hypotension in Nitroglycerine Tilt-Induced Vasovagal Syncope. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 739-748.	0.5	20
33	The role of the atrial electromechanical delay in predicting atrial fibrillation in beta-thalassemia major patients. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 48, 147-157.	0.6	20
34	Sudden cardiac death in neuromuscular disorders: Time to establish shared protocols for cardiac pacing. <i>International Journal of Cardiology</i> , 2016, 207, 284-285.	0.8	19
35	Nursing Teleconsultation for the Outpatient Management of Patients with Cardiovascular Disease during COVID-19 Pandemic. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2087.	1.2	19
36	Atrial fibrillation burden in Myotonic Dystrophy type 1 patients implanted with dual chamber pacemaker: the efficacy of the overdrive atrial algorithm at 2 year follow-up. <i>Acta Myologica</i> , 2013, 32, 142-7.	1.5	18

#	ARTICLE	IF	CITATIONS
37	Does cardiac pacing reduce syncopal recurrences in cardioinhibitory vasovagal syncope patients selected with head-up tilt test? Analysis of a 5-year follow-up database. <i>International Journal of Cardiology</i> , 2018, 270, 149-153.	0.8	17
38	Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 421-427.	1.0	17
39	Cardiac pacing procedures during coronavirus disease 2019 lockdown in Southern Italy: insights from Campania Region. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 857-859.	0.6	17
40	Rate and impact on patient outcome and healthcare utilization of complications requiring surgical revision: Subcutaneous versus transvenous implantable defibrillator therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 1712-1723.	0.8	17
41	The clinical performance of dabigatran in the Italian real-life experience. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 922-923.	0.6	16
42	Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients. <i>Frontiers in Pharmacology</i> , 2020, 11, 582348.	1.6	15
43	Electrophysiological Study Prognostic Value and Long-Term Outcome in Drug-Induced Type 1 Brugada Syndrome. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 1264-1273.	1.3	15
44	Direct Oral Anticoagulants Plasma Levels Measurement: Clinical Usefulness from Trials and Real-World Data. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 150-160.	1.5	14
45	Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1621.	1.0	13
46	COVID-19 and cardiac implantable electronic device remote monitoring: crocodile tears or new opportunity? <i>Expert Review of Medical Devices</i> , 2020, 17, 471-472.	1.4	13
47	Autonomic Nervous System Modulation before the Onset of Sustained Atrioventricular Nodal Reentry Tachycardia. <i>Annals of Noninvasive Electrocardiology</i> , 2010, 15, 49-55.	0.5	12
48	Interatrial block to predict atrial fibrillation in myotonic dystrophy type 1. <i>Neuromuscular Disorders</i> , 2018, 28, 327-333.	0.3	11
49	Arrhythmias and Sudden Cardiac Death in Beta-Thalassemia Major Patients: Noninvasive Diagnostic Tools and Early Markers. <i>Cardiology Research and Practice</i> , 2019, 2019, 1-8.	0.5	11
50	Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients with Atrial Fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 970-976.	1.5	11
51	Cardiovascular Involvement in mtDNA Disease. <i>Heart Failure Clinics</i> , 2021, 18, 51-60.	1.0	11
52	Far field R-wave sensing in Myotonic Dystrophy type 1: right atrial appendage versus Bachmann's bundle region lead placement. <i>Acta Myologica</i> , 2014, 33, 94-9.	1.5	11
53	Electrophysiological Adverse Effects of Direct Acting Antivirals in Patients With Chronic Hepatitis C. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 924-930.	1.0	10
54	Effects of defibrillation shock in patients implanted with a subcutaneous defibrillator: a biomarker study. <i>Europace</i> , 2018, 20, f233-f239.	0.7	10

#	ARTICLE	IF	CITATIONS
55	Update on Direct oral anticoagulants in atrial fibrillation patients undergoing cardiac interventional procedures. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 75, 1.	0.8	10
56	Long-term progression of rhythm and conduction disturbances in pacemaker recipients: findings from the Pacemaker Expert Programming study. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 357-365.	0.6	9
57	Adenosine-induced sinus tachycardia in a patient with Myotonic Dystrophy type 1. <i>Acta Myologica</i> , 2014, 33, 104-6.	1.5	9
58	The Impact of the COVID-19 Outbreak on Patients' Adherence to PCSK9 Inhibitors Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 475.	1.0	9
59	Prevalence and clinical predictors of inappropriate direct oral anticoagulant dosage in octogenarians with atrial fibrillation. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 879-886.	0.8	9
60	Which Is the True Epidemiology of Atrial Fibrillation in Myotonic Dystrophy Type 1 Patients?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 1418-1419.	0.5	8
61	Acute shock efficacy of the subcutaneous implantable cardioverter-defibrillator according to the implantation technique. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 1695-1703.	0.8	8
62	Increased heterogeneity of ventricular repolarization in myotonic dystrophy type 1 population. <i>Acta Myologica</i> , 2016, 35, 100-106.	1.5	8
63	Management of older patients with unexplained, recurrent, traumatic syncope and bifascicular block: Implantable loop recorder versus empiric pacemaker implantation—Results of a propensity-matched analysis. <i>Heart Rhythm</i> , 2022, 19, 1696-1703.	0.3	8
64	Cardiopulmonary resuscitation in pectus excavatum patients: Is it time to say more?. <i>Resuscitation</i> , 2015, 88, e5-e6.	1.3	7
65	The importance of a correct methodological approach for the arrhythmic risk evaluation in beta thalassemia major patients. <i>International Journal of Cardiology</i> , 2016, 225, 107-108.	0.8	7
66	Temperament and character personality dimensions in nitrate-tilt-induced vasovagal syncope patients. <i>Hellenic Journal of Cardiology</i> , 2017, 58, 411-416.	0.4	7
67	The Controversial Epidemiology of Left Ventricular Dysfunction in Patients With Myotonic Dystrophy Type 1. <i>JAMA Cardiology</i> , 2017, 2, 1044.	3.0	7
68	Arrhythmogenic syncope leading to cardiac rhythm management procedures during COVID-19 lockdown. <i>Expert Review of Medical Devices</i> , 2020, 17, 1207-1210.	1.4	7
69	Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation. <i>Journal of Blood Medicine</i> , 2020, Volume 11, 77-81.	0.7	7
70	Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. <i>Journal of Clinical Medicine</i> , 2021, 10, 1569.	1.0	7
71	Are there real benefits to implanting cardiac devices in patients with end-stage dilated dystrophinopathic cardiomyopathy? Review of literature and personal results. <i>Acta Myologica</i> , 2019, 38, 1-7.	1.5	7
72	Cardioinhibitory syncope with asystole during nitroglycerin potentiated head up tilt test: prevalence and clinical predictors. <i>Clinical Autonomic Research</i> , 2022, 32, 167-173.	1.4	7

#	ARTICLE	IF	CITATIONS
73	Bachmann bundle pacing reduces atrial electromechanical delay in type 1 myotonic dystrophy patients. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 51, 229-236.	0.6	6
74	Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study. <i>BioMed Research International</i> , 2019, 2019, 1-6.	0.9	6
75	Role of electrophysiological evaluation for the best device choice to prevent sudden cardiac death in patients with Myotonic Dystrophy Type 1 and Emery Dreifuss Muscular Dystrophy. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, e1-e2.	2.3	6
76	Lead Abandonment and Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD) Implantation in a Cohort of Patients With ICD Lead Malfunction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 692943.	1.1	6
77	Heart rate distribution in paced and non-paced patients with severe recurrent reflex syncope and tilt-induced asystole: Findings from the BIOSync CLS study. <i>International Journal of Cardiology</i> , 2021, 335, 52-54.	0.8	6
78	Cardiac implantable electronic devices replacements in patients followed by remote monitoring during COVID-19 lockdown. <i>European Heart Journal Digital Health</i> , 2021, 2, 171-174.	0.7	5
79	Safety of Omitting Defibrillation Efficacy Testing With Subcutaneous Defibrillators: A Propensity-Matched Case-Control Study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, CIRCEP121010381.	2.1	5
80	Arrhythmic risk evaluation in myotonic dystrophy: the importance of selection criteria and methodological approach. <i>Clinical Autonomic Research</i> , 2017, 27, 203-204.	1.4	4
81	Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score-Matched Study. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1003-1007.	1.3	4
82	Cardiac resynchronization therapy defibrillators in patients with permanent atrial fibrillation. <i>ESC Heart Failure</i> , 2021, , .	1.4	4
83	Which parameters describe the electrophysiological properties of successful slow pathway RF ablation in patients with common atrioventricular nodal reentrant tachycardia?. <i>Anatolian Journal of Cardiology</i> , 2010, 10, 126-129.	0.4	3
84	Effectiveness of Implantable DEfibrillators Alert Systems: comparison between audible and vibratory alert: IDEAS study. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 114-121.	0.6	3
85	Voltage-directed cavo-tricuspid isthmus ablation using a novel ablation catheter mapping technology in a myotonic dystrophy type I patient. <i>Acta Myologica</i> , 2016, 35, 109-113.	1.5	3
86	Remote Monitoring of Atrial High Rate Episodes in Pacemaker Patients. The Rapid Study Design. <i>Journal of Atrial Fibrillation</i> , 2018, 11, 2075.	0.5	3
87	Optimal left ventricular lead placement for cardiac resynchronization therapy in postmyocardial infarction patients. <i>Future Cardiology</i> , 2018, 14, 215-224.	0.5	2
88	Non Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients Scheduled for Electrical Cardioversion: A Real-Life Propensity Score Matched Study. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 413-420.	0.7	2
89	ST-elevation during head up tilt test: a challenging case in syncope unit. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.3	2
90	Single-Chamber Leadless Cardiac Pacemaker in Patients Without Atrial Fibrillation: Findings From Campania Leadless Registry. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 781335.	1.1	2

#	ARTICLE	IF	CITATIONS
91	Usefulness of the MAGGIC Score in Predicting the Competing Risk of Non-Sudden Death in Heart Failure Patients Receiving an Implantable Cardioverter-Defibrillator: A Sub-Analysis of the OBSERVO-ICD Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 121.	1.0	2
92	Atrial fibrillation in beta thalassemia major: how to perform effective screening and early detection. <i>Hematology</i> , 2017, 22, 368-369.	0.7	1
93	The "Obesity Paradox" and the Use of NOAC. , 2021, , 149-178.		1
94	Edoxaban (LIXIANA®) in the treatment of venous thromboembolism. <i>Future Cardiology</i> , 2021, 17, 779-791.	0.5	1
95	Use of Cardiac Contractility Modulation as Bridge to Transplant in an Obese Patient With Advanced Heart Failure: A Case Report. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 833143.	1.1	1
96	Pancarditis as the Clinical Presentation of Eosinophilic Granulomatosis with Polyangiitis: A Multimodality Approach to Diagnosis. <i>Neurology International</i> , 2022, 12, 133-141.	0.2	1
97	Appropriate ICD Interventions for Ventricular Arrhythmias Are Predicted by Higher Syntax Scores I and II in Patients with Ischemic Heart Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 1843.	1.0	0
98	Polycystic ovary syndrome and arrhythmic risk: the role of comorbidities and the prevalence of interatrial block. <i>Anatolian Journal of Cardiology</i> , 2016, 16, 730.	0.5	0